Bernstein warns of 33% downside for Novo Nordisk (NVO) stock, slashing EPS estimates as Eli Lilly's competitive threat intensifies in GLP-1 obesity drugs. The post Novo Nordisk (NVO) Stock Plunges: Bernstein Warns of 33% Drop Amid Eli Lilly Rivalry appeared first on Blockonomi.